Pierre Fabre Hopes To Enter US Cancer Space With Atara’s Ebvallo
Deal Snapshot: The French company already holds rights to the allogeneic T-cell therapy in much of the world, but will pay Atara $30m up front to obtain rights in the US, Canada and elsewhere.
You may also be interested in...
Restructuring Edition: The financial market is beginning to perk up after a decline in biopharma financings at the end of 2023, but some companies still are struggling to stay afloat after assessing their strategic options, like Merrimack and LianBio, which announced plans to dissolve.
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.